Genmab AS (FRA:GE91) Operating Margin %: 25.11% (As of Mar. 2026) — 43% Below Median


FRA:GE91 Genmab AS FRA:GE91
93 GF Score
Price €21.80
GF Value €29.03
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Genmab AS Operating Margin %?

Genmab AS FRA:GE91 +0.93% 93 Operating Margin % is 25.11% as of Mar. 2026, which is 43% below its 10-year median of 44.42. GuruFocus rates FRA:GE91 with a GF Score™ of 93/100 and a GF Value™ of €29.03 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 945 Biotechnology companies, Genmab AS ranks better than 94.07% on this metric.

Operating Margin % is calculated as Operating Income divided by its Revenue. Genmab AS's Operating Income for the three months ended in Mar. 2026 was €195 Mil. Genmab AS's Revenue for the three months ended in Mar. 2026 was €775 Mil. Therefore, Genmab AS's Operating Margin % for the quarter that ended in Mar. 2026 was 25.11%.

Warning Sign:

Genmab AS operating margin has been in a 5-year decline. The average rate of decline per year is -9.8%.

The historical rank and industry rank for Genmab AS's Operating Margin % or its related term are showing as below:

FRA:GE91' s Operating Margin % Range Over the Past 10 Years
Min: 32.3   Med: 44.42   Max: 62.44
Current: 32.98


FRA:GE91's Operating Margin % is ranked better than
94.07% of 945 companies
in the Biotechnology industry
Industry Median: -86.77 vs FRA:GE91: 32.98

Genmab AS's 5-Year Average Operating Margin % Growth Rate was -9.80% per year.

Genmab AS's Operating Income for the three months ended in Mar. 2026 was €195 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Mar. 2026 was €1,105 Mil.


Genmab AS  (FRA:GE91) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Genmab AS Operating Margin % Related Terms


Genmab AS Operating Margin % Historical Data

* Premium members only.

The historical data trend for Genmab AS's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Genmab AS Operating Margin % Chart

Genmab AS Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Operating Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 35.08 43.21 32.30 32.52 33.60

Genmab AS Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 26.29 38.92 44.91 22.97 25.11

FRA:GE91 vs VRTX, REGN, ALNY: Operating Margin % Comparison

For the Biotechnology subindustry, Genmab AS's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Genmab AS Operating Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Genmab AS's Operating Margin % distribution charts can be found below:

* The bar in red indicates where Genmab AS's Operating Margin % falls into.


FRA:GE91
93GF Score
Genmab AS FRA:GE91
Operating Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Genmab AS Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Genmab AS's Operating Margin % for the fiscal year that ended in Dec. 2025 is calculated as

Operating Margin %=Operating Income (A: Dec. 2025 ) / Revenue (A: Dec. 2025 )
=1067.5 / 3176.88
=33.60 %

Genmab AS's Operating Margin % for the quarter that ended in Mar. 2026 is calculated as

Operating Margin %=Operating Income (Q: Mar. 2026 ) / Revenue (Q: Mar. 2026 )
=194.625 / 775.04
=25.11 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Operating Margin % →
What does a Operating Margin % of 25.11% mean?
Genmab AS (FRA:GE91) has a Operating Margin % of 25.11% as of Mar. 2026. Operating margin is the ratio of total operating income to net sales. View historical data on Genmab AS and its competitors. This is 43% below median its historical median of 44.42. Over the past decade, Genmab AS's Operating Margin % has ranged from 32.30 to 62.44. According to the industry distribution chart, Genmab AS ranks #56 out of 945 companies in the Biotechnology industry, placing it in the top 5.9%.
Is Genmab AS's Operating Margin % too high?
Genmab AS's current Operating Margin % of 25.11% is 43% below median its 10-year median of 44.42. Over the past 10 years, this metric has ranged from a low of 32.30 to a high of 62.44. Based on the distribution chart, Genmab AS ranks #56 out of 945 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Genmab AS has a GF Score™ of 93/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Genmab AS's Operating Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Genmab AS ranks #56 out of 945 companies for Operating Margin %. This places Genmab AS in the top 6% of its industry — outperforming the majority of peers. Historically, Genmab AS's own Operating Margin % has ranged from 32.30 to 62.44 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Margin % for a Biotechnology company?
A good Operating Margin % depends on the Biotechnology industry context. However, Operating Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Margin % mean?
A high Operating Margin % can signal that a stock is expensive relative to its fundamentals. Operating margin is the ratio of total operating income to net sales. View historical data on Genmab AS and its competitors. Genmab AS's current Operating Margin % is 25.11%, which is 43% below median its own 10-year median of 44.42. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genmab AS stock overvalued right now?
Based on GuruFocus' analysis, Genmab AS (FRA:GE91) is currently considered Modestly Undervalued. The stock's GF Value™ is €29.03, compared to a current price of €21.80 — trading 24.9% below its estimated fair value. The current Operating Margin % is 25.11%, which is 43% below median its 10-year median of 44.42. Genmab AS's overall GF Score™ is 93/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Margin % calculated?
Operating Margin % is calculated from a company's financial statements. For Genmab AS (FRA:GE91), the current Operating Margin % is 25.11% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Genmab AS (FRA:GE91) Overvalued in 2026?

Based on GuruFocus' analysis, Genmab AS stock appears to be undervalued. The current stock price of €21.80 is trading 24.9% below its estimated GF Value™ of €29.03. GuruFocus considers Genmab AS to be Modestly Undervalued.

Key valuation signals for FRA:GE91:

  • Operating Margin %: 25.11% (43% below median its 10-year median of 44.42)
  • GF Value™: €29.03 vs. price of €21.80 (24.9% below fair value)
  • GF Score™: 93/100 with 5 warning signs

No single metric tells the full story. See the FRA:GE91 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Genmab AS Business Description

Address Carl Jacobsens Vej 30, Valby, DNK, 2500
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
93GF Score

Get the complete analysis for FRA:GE91

Operating Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€21.80
Price
€29.03
GF Value